-
1 × ₨ 55.80
-
1 × ₨ 75.00
-
1 × ₨ 432.00
-
1 × ₨ 560.00
-
1 × ₨ 333.00
-
1 × ₨ 68.00
-
1 × ₨ 460.00
-
1 × ₨ 616.00
-
1 × ₨ 2,500.00
-
1 × ₨ 320.00
-
1 × ₨ 720.00
-
4 × ₨ 680.00
-
1 × ₨ 250.00
-
2 × ₨ 75.00
-
1 × ₨ 526.00
-
1 × ₨ 4,129.02
-
1 × ₨ 135.00
-
2 × ₨ 139.87
-
1 × ₨ 535.00
-
1 × ₨ 20.00
-
1 × ₨ 1,680.00
-
1 × ₨ 1,345.00
-
1 × ₨ 528.00
-
1 × ₨ 325.00
-
1 × ₨ 17.11
-
1 × ₨ 835.00
-
2 × ₨ 271.60
-
1 × ₨ 10.00
-
1 × ₨ 504.66
-
2 × ₨ 2,848.96
-
1 × ₨ 184.88
-
1 × ₨ 1,109.60
-
1 × ₨ 250.00
-
1 × ₨ 186.00
-
1 × ₨ 30.00
-
1 × ₨ 629.18
-
1 × ₨ 1,600.00
-
1 × ₨ 80.00
-
1 × ₨ 500.00
-
1 × ₨ 1,520.00
-
1 × ₨ 161.00
-
1 × ₨ 202.36
-
1 × ₨ 596.64
-
1 × ₨ 1,600.00
-
1 × ₨ 125.00
-
1 × ₨ 336.00
-
1 × ₨ 720.00
-
1 × ₨ 120.00
-
1 × ₨ 91.14
-
1 × ₨ 53.00
-
1 × ₨ 430.00
-
1 × ₨ 310.00
-
1 × ₨ 500.00
-
1 × ₨ 40.00
-
1 × ₨ 400.00
-
1 × ₨ 250.00
-
1 × ₨ 63.00
-
1 × ₨ 1,155.00
-
1 × ₨ 236.00
-
1 × ₨ 265.00
-
1 × ₨ 194.93
-
1 × ₨ 120.00
Roll over image to zoom in
SITAPIN 50MG
₨ 277.00₨ 308.00 (-10%)
- For use as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus.
- Also for use in patients with type 2 diabetes mellitus to improve glycemic control in combination with metformin or a PPARγ agonist (e.g., thiazolidinediones) when the single agent alone, with diet and exercise, does not provide adequate glycemic control.
Sitagliptin is a new oral hypoglycemic (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. This enzyme-inhibiting drug is to be used either alone or in combination with metformin or a thiazolidinedione for control of type 2 diabetes mellitus. The drug works to competitively inhibit a protein/enzyme, dipeptidyl peptidase 4 (DPP-4), that results in an increased amount of active incretins (GLP-1 and GIP), reduced amount of release of glucagon (diminishes its release) and increased release of insulin.
Reviews
There are no reviews yet.